Serzan is a medical oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, as well as an instructor of medicine at Harvard Medical School, located in Boston.
Breaking Down Clinical Trial Participation in Kidney Cancer: Is it Right for You?
Dr. Michael Serzan emphasizes the importance of clinical trial participation for patients with kidney cancer.
Zanzalintinib Triplet Combo Under Investigation in Kidney Cancer Subgroups
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
A New Therapeutic Approach May Make Waves in Kidney Cancer Treatment
Dr. Michael Serzan provides expert takeaways on treatment updates for patients with early-stage kidney cancer following the 2025 ASCO Meeting.